NCT06198712 - A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 12, 2023

Primary Completion Date

August 8, 2029

Study Completion Date

August 8, 2029

Conditions

Sickle Cell Disease

Interventions

DRUG

Etavopivat

Participants will receive oral tablets of etavopivat once daily.

Trial Locations (15)

1130

WITHDRAWN

Acibadem Adana Hospital, Seyhan

20200

NOT_YET_RECRUITING

KEMRI-Walter-Reed Kericho, Kericho

40100

RECRUITING

Ahero Clinical Trials Unit, Kisumu, Kenya, Kisumu

NOT_YET_RECRUITING

Kombewa Clinical Research Centre, Kisumu

NOT_YET_RECRUITING

Kenya Medical Research Institute-Centre for Respiratory Disease Research, Siaya Clinical Research Annexe, Siaya

102215

RECRUITING

Lagos University Teaching Hospital, Lagos, Lagos

700101

NOT_YET_RECRUITING

Aminu Kano Teaching Hospital (AKTH), Tarauni

M5G 1X8

WITHDRAWN

The Hospital for Sick Children, Toronto

1107 2020

RECRUITING

American University of Beirut Medical center, Beirut

113-6044

RECRUITING

Hospital Nini, Tripoli

00000

RECRUITING

University of Nigeria Teaching Hospital, Enugu, Enugu

06100

WITHDRAWN

Hacettepe University pediatric hematology, Ankara

SE1 7EH

RECRUITING

Guys and St Thomas NHS Foundation Trust / Evelina Childrens Hospital, London

SE5 9RS

RECRUITING

Kings College Hospital NHS Foundation Trust, London

M13 9WL

RECRUITING

Manchester Royal Infirmary, Manchester